Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.

Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R.

Breast Cancer Res. 2011;13(6):R117. doi: 10.1186/bcr3060.

2.

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D.

J Transl Med. 2015 Jun 27;13:204. doi: 10.1186/s12967-015-0567-0.

5.

Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.

Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, Pecorelli S, Cannon M, Parham GP.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1345-55.

PMID:
12459356
6.

Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature.

Inokuma M, dela Rosa C, Schmitt C, Haaland P, Siebert J, Petry D, Tang M, Suni MA, Ghanekar SA, Gladding D, Dunne JF, Maino VC, Disis ML, Maecker HT.

J Immunol. 2007 Aug 15;179(4):2627-33.

7.

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ.

Breast Cancer Res. 2015 May 23;17:71. doi: 10.1186/s13058-015-0584-1.

8.

Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.

Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Dec;52(12):771-9.

PMID:
13680193
9.

The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.

zum Büschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H.

J Immunol. 2001 Aug 1;167(3):1712-9.

10.

Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.

Decker T, Fischer G, Bücke W, Bücke P, Stotz F, Grüneberger A, Gropp-Meier M, Wiedemann G, Pfeiffer C, Peschel C, Götze K.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1945-50. doi: 10.1007/s00432-012-1258-3.

PMID:
22760213
11.

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.

Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanoviç S, Wallwiener D, Gückel B.

Clin Cancer Res. 2003 Oct 1;9(12):4376-86.

12.

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunol. 2002 Sep 1;169(5):2756-61.

13.

Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy.

Song G, Wang X, Jia J, Yuan Y, Wan F, Zhou X, Yang H, Ren J, Gu J, Lyerly HK.

Cancer Immunol Immunother. 2013 Jun;62(6):1123-30. doi: 10.1007/s00262-013-1424-8.

PMID:
23604172
14.
16.

In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells.

Kass R, Agha J, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD.

J Surg Res. 2003 Jun 15;112(2):189-97.

PMID:
12888337
17.

Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.

Tsang JY, Hui SW, Ni YB, Chan SK, Yamaguchi R, Kwong A, Law BK, Tse GM.

Breast Cancer Res Treat. 2014 Jan;143(1):1-9. doi: 10.1007/s10549-013-2781-x.

PMID:
24272079
18.

Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Breast Cancer Res Treat. 2006 Jul;98(1):17-29.

PMID:
16758122
19.

Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients.

Ferrari S, Malugani F, Rovati B, Porta C, Riccardi A, Danova M.

Oncol Rep. 2005 Jul;14(1):113-20.

PMID:
15944777
20.

A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.

Gückel B, Stumm S, Rentzsch C, Marmé A, Mannhardt G, Wallwiener D.

Cancer Immunol Immunother. 2005 Feb;54(2):129-40.

PMID:
15365776
Items per page

Supplemental Content

Support Center